Last reviewed · How we verify

Metformin plus folic acid

University Magna Graecia · FDA-approved active Small molecule

Metformin reduces hepatic glucose production and improves insulin sensitivity, while folic acid serves as a methyl donor and cofactor for nucleotide synthesis.

Metformin reduces hepatic glucose production and improves insulin sensitivity, while folic acid serves as a methyl donor and cofactor for DNA synthesis and homocysteine metabolism. Used for Type 2 diabetes mellitus, Prevention of B12 deficiency and homocysteine elevation in metformin-treated patients.

At a glance

Generic nameMetformin plus folic acid
SponsorUniversity Magna Graecia
Drug classAntidiabetic agent with vitamin supplement
TargetAMPK (metformin); folate receptors and methylenetetrahydrofolate reductase (folic acid)
ModalitySmall molecule
Therapeutic areaEndocrinology / Diabetes
PhaseFDA-approved

Mechanism of action

Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, primarily through AMPK activation and mitochondrial effects. Folic acid supplementation addresses potential metformin-induced B12 malabsorption and supports one-carbon metabolism, which may reduce homocysteine levels and support cellular methylation reactions. This combination is used to optimize glycemic control while mitigating metformin-associated micronutrient depletion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: